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S208 Poster Session Ipatients (93%) completed collection within the predicted number of
apheresis sessions (78% for G and 100% for G + P, P5 0.03). Nine-
teen (68%) of the patients included in the validation cohort have re-
ceived a first autologous transplant. Median cell dose was 3.81 106
(range 3.04-4.42 x106) CD34+/kg for the 8 patients in the G ap-
proach and 4.99  106 (range 3.00-7.49 x106) CD34+/kg for the
11 patients in the G + P approach. There was no difference between
approaches in time for absolute neutrophil count. 500/mm2 (me-
dian 12 days vs. 13 days for G and G + P respectively, P5 0.07) or
platelet count. 20,000/mm2 without platelet transfusion (median
11.5 days vs. 13 days for G and G + P respectively, P5 0.09)
Conclusion: The MUSC mobilization algorithm is a data-gener-
ated and accurate tool to decide on the utilization of plerixafor for
mobilization, starting on the 4th day of G-CSF. This approach is
likely to save on mobilization costs compared to the ‘‘on label’’ use
of plerixafor in all MM and NHL mobilizations.
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READMISSION RATES AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Mohan, S., Overman, R., Dean, R., Smith, S., Kalaycio,M., Pohlman, B.,
Sweetenham, J., Sobecks, R., Andresen, S., Copelan, E., Bolwell, B. Cleve-
land Clinic Taussig Cancer Institute, OH
With increasing scrutiny of healthcare expenditures, policy pro-
posals have highlighted the reduction in hospital readmission rates
as a method by which to improve the cost and the quality of medical
care. To date, readmission rates following bone marrow transplanta-
tion procedures have been sparsely described. A retrospective review
of consecutive patients who underwent autologous hematopoietic
stem cell transplantation (AHSCT) at a single institution over
a five-year period was performed to determine the number and
causes of readmission within one year post-transplantation. Each re-
admission was classified according to the primary presenting symp-
tom or an identified etiology following inpatient clinical evaluation.
485 patients received high-dose chemotherapy followed by an
AHSCT from 1/2004 to 12/2008 for varied disease indications in-
cluding non-Hodgkin lymphoma (n5 252, 52%), multiplemyeloma
and/or amyloidosis (124, 26%), Hodgkin lymphoma (83, 17%), and
other malignant diseases (26, 5%). Of these, 142 (29%) required at
least one inpatient readmission within one year, accounting for
216 discrete events. 45 patients (9%) were readmitted more than
once. 60 of all readmissions (28%) occurred within the first 30
days of transplantation, and 131 (61%) within the first 100 days.
45% of all readmissions were due to infection or unexplained fever,
17% to gastrointestinal causes, 13% to relapsed disease or new sec-
ondary malignancy, 8% to cardiopulmonary symptoms, and 6% to
neurological symptoms, with the remainder of admissions related
to thromboembolic disease, refractory pain symptoms, hepatic dys-
function, or other causes. Among those patients admitted within
30 days, 63% presented with infection or fever and 23%with gastro-
intestinal symptoms. The majority of those readmitted with gastro-
intestinal toxicity (9/14) were patients with non-Hodgkin
lymphoma. Further study of this high-risk patient group and of the
reasons for readmissionmay identify outpatient supportive caremea-
sures that could be enacted to decrease both AHSCT-related mor-
bidity and associated healthcare costs.135
PLERIXAFOR GIVEN ‘‘JUST IN TIME’’ FOR PERIPHERAL BLOOD STEM
CELL MOBILIZATION OF PATIENTS WITH SUBOPTIMAL RESPONSE TO
G-CSF
Horwitz, M., Khan, T., Long, G., Gasparetto, C., Sullivan, K., Chute, J.,
Rizzieri, D., Drago, S., Chao, N. Duke University Health System, Dur-
ham, NC
Plerixafor reversibly inhibits binding of stromal cell-derived factor
1 alpha to the chemokine receptor CXCR4 resulting in mobilization
of bone marrow hematopoietic progenitor cells. Phase III studies
demonstrate that plerixafor given on day 4 of G-CSF treatment sig-
nificantly improves the chances of successful peripheral blood stemcell collection compared to G-CSF alone in patients with multiple
myeloma (MM) and non-Hodgkin lymphoma (NHL). In the context
of an IRB approved phase II clinical trial, we studied whether plerix-
afor could be used to rescue patients who demonstrate a suboptimal
mobilization response to five doses of G-CSF(10mg/kg). Patients
were eligible for protocol therapy if, on day 5 of G-CSF, there was
less than 7 circulating CD34+ cells/ml. In addition, patients with 7
to 20 circulating CD34+ cells/ml were eligible for protocol therapy
if \1.3  106 CD34+ cells/kg were collected on the first day of
apheresis. These patients were felt to be at high-risk for inadequate
stem cell collection. Subjects were given plerixafor (0.24 mg/kg) at
10:00PMof day 5 of G-CSF therapy. This process of an evening dos-
ing with plerixafor followed the next morning by G-CSF and apher-
esis was repeated for up to a total of 3 days of apheresis or until$5
106 cells/kg were collected. The primary endpoint of the study is the
percentage of patients who collected at least 2 106 CD34+ cells/kg.
Nine subjects (median age 59) have been accrued to the trial (MM 3,
NHL 5, Hodgkin Lymphoma 1), with the results demonstrated in
the table. Five of nine subjects had less than 7 circulating CD34+
cells/kg on Day 5 of G-CSF mobilization. The circulating CD34+
cell level increased a mean of 2.8 fold after the first dose of plerixafor
and a mean of 1.8 fold after the second dose of plerixafor. All nine
subjects achieved the primary endpoint of the study (collection of
.2 106 CD34+ cells/kg). Plerixafor was well tolerated with no ad-
verse events.grade 1. In conclusion, plerixafor can be given ‘‘just in
time’’ to rescue patients with a poormobilization response toG-CSF
alone. Further studies are needed to assess themost cost effective way
of using this potent stem cell mobilizing agent.
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RITUXIMAB AND SARGRAMOSTIM IMMUNOTHERAPY FOLLOWING AU-
TOLOGOUS STEM CELL TRANSPLANT FOR AGGRESSIVE NON-HODGKIN’S
LYMPHOMA
Scigliano, E., Grosskreutz, C.L., Osman, K., Malone, A., Nieto, J.,
Isola, L.M. Mount Sinai Medical Center, New York, NY
Introduction: High dose chemotherapy with autologous stem cell
transplant (ASCT) improves survival in patients with aggressive
non-Hodgkin’s lymphoma (NHL), but relapse occurs in 40-50%
of patients. Rituximab exerts its anti-tumor effect through comple-
ment and antibody-dependent cell cytotoxicity (ADCC). Sargramos-
tim is involved in the activation and differentiation of macrophages
and dendritic cells and increases monocyte-mediated ADCC. The
addition of sargramostim to rituximabmay potentiate the anti-tumor
effect of rituximab by enhancing recruitment and activation of effec-
tor cells that mediate ADCC.We evaluated the safety and efficacy of
rituximab and sargramostim given as ‘‘adjuvant immunotherapy’’ to
patients following ASCT for aggressive NHL.
Patients andMethods: 8 patients (5 male, 3 female; median age 53,
range 34-69) with CD20+ diffuse large B cell (6) or mantle cell (2)
NHL relapsed, primary refractory or in first complete remission (in-
termediate-high or high risk IPI) underwent stem cell mobilization
using rituximab and cyclophosphamide followed by high dose
Poster Session I S209chemotherapy with rituximab, carmustine, etoposide, cytarabine and
melphalan. Adjuvant immunotherapy consisted of rituximab
375 mg/M2 IV weekly and sargramostim 250 ug s.c. TIW during
weeks 5 to 8 and 24 to 27 post transplant.
Results: Seven patients had successful mobilization (mean CD34/kg
collected 12.5E6 and infused 9E6) and underwent transplant. Me-
dian time to neutrophil and platelet engraftment was 9 and 10 days
respectively. Six patients are alive with no evidence of disease from
3 to 18 months post transplant. One patient relapsed at 11 months.
4/4 patients receiving at least once cycle of adjuvant immunotherapy
developed grade 1 to 4 neutropenia from 3 to 34 weeks post adjuvant
rituximab. Neutrophil counts recovered following treatment with
G-CSF, but recurred in all 4 patients without additional exposure
to rituximab. One patient who had engrafted platelets developed
grade 2 thrombocytopenia on day 33 post transplant. Platelets spon-
taneously recovered.
Conclusions: Delayed-onset neutropenia is a known complication
of rituximab. The incidence may be higher when rituximab is used
following ASCT. It is not clear if the timing of rituximab administra-
tion post transplant or the concomitant use of sargramostim contrib-
uted to the high incidence of delayed neutropenia in this study.
Larger studies and longer followupwill be needed to determine if ad-
juvant immunotherapy decreases relapse.137
CONSOLIDATION THERAPY FOLLOWING AUTOLOGOUS STEM CELL
TRANSPLANTATION FOR NON-HODGKINS AND HODGKINS LYMPHOMAS
Colvin, G.A., Milani, C., Berz, D., Quesenberry, P. Brown University,
Providence, RI
Purpose: To determine whether autologous stem-cell transplanta-
tion (ASCT) followed by consolidation with Rituximab or irradia-
tion is superior to ASCT alone in adults with advanced or relapsed
lymphoma.
Patients and Methods: Fourteen consecutive lymphoma patients
were entered onto this prospective, single center, phase II study. Sev-
enteen previously transplanted patients were used as historical con-
trols with continuous follow-up. Patients with non-Hodgkin’s
lymphoma (NHL, n5 11) or Hodgkin’s disease (HD, n5 3) re-
ceived ASCT followed by consolidation with Rituximab (375 mg/
m2/week x4, every 6 months x5) or irradiation (20-30 Gy) respec-
tively.
Results: Age, diagnosis (NHL vs. HD), B symptoms, risk factors,
LDH, previous treatment response and histological type were well
balanced between the two groups. With a median follow-up of
21.3 months, the 30-month relapse rate was 23% and 53%
(P5 0.045), disease-free survival was 70% and 41% (P5 0.03) and
overall survival was 73% and 47% (P5 0.07) for the consolidation
group and historical controls, respectively. A multivariate analysis
showed that age$ 55 and abnormal pre-transplant LDH were pre-
dictors of poor outcome. When NHL patients were analyzed sepa-
rately (n5 24), 30-month relapse rate was 27% and 63%
(P5 0.08), disease free survival was 73% and 47% (P5 0.05) and
overall survival was 70% and 40% (P5 0.06) for consolidation and
control arms, respectively.
Conclusion:The use of ASCT followed by consolidation using Rit-
uximab (NHL) or irradiation (HD) in adults with advanced lym-
phoma showed a markedly decreased relapse rate and improved
disease free and overall survival compared with conventional
ASCT. The NHL subgroup (Rituximab) also demonstrated that
consolidation produced a marked advantage.138
COMBINED AMIFOSTINE AND CRYOTHERAPY FOR PREVENTION OF
ORAL MUCOSITIS (OM) FOLLOWING HIGH DOSE CHEMOTHERAPY
WITH MELPHALAN AND AUTOLOGOUS HEMATOPOIETIC CELL TRANS-
PLANT (HCT) FOR MULTIPLE MYELOMA (MM)
Lopez-Bover, M., Thompson, M., Santos, V., Holder, M., Feinstein, L.,
Grosman, D. Memorial Cancer Institute, Pembroke Pines, FLOM is a major cause of morbidity following autologous HCT
for MM. Amifostine is a free radical scavenger that reduces proin-
flammatory cytokine production. Cryotherapy causes vasoconstric-
tion of vessels in the oral cavity. Randomized controlled trials
have demonstrated a significant reduction in the severity and du-
ration of OM when amifostine or cryotherapy is administered
with high dose melphalan prior autologous HCT for MM. To
date, no report has been made of outcomes when both treatments
are used concurrently.
We performed 28 autologous HCTs on 21 patients with MM
in an outpatient setting. Patients received amifostine 740 mg/m2
24 hours prior to and immediately prior to melphalan (200 mg/
m2 for 19 patients and 140 mg/m2 for 2 patients; dose depen-
dent on renal function). Cryotherapy was administered for four
hours beginning 30 minutes prior to the administration of mel-
phalan. Six patients had a decline in systolic blood pressure
of$ 20% of baseline following the administration of amifostine.
Aggressive intravenous hydration and Trendeleberg positioning
resulted in the rapid return to baseline blood pressure in all
cases. Prehydration and holding antihypertensive medications
for 24 hours prior to the first dose of amifostine reduced symp-
tomatic hypotension.
No patient was admitted for OM. The one patient who required
both total parenteral nutrition and narcotic analgesics for grade III
OM did not remove his dentures during cryotherapy. One patient
experienced grade II OM that was managed with oral narcotic anal-
gesics. The remaining 19 patients experiencing either grade I (n5 1)
or no (n5 18) OM. Combined amifostine and cryotherapy is a well-
tolerated and effective method of reducing OM following high dose
melphalan and autologous HCT for MM.139
AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RE-
FRACTORY OR RELAPSED HODGKIN DISEASE IN COLOMBIA
Linares, A.1,2, Abello, V.1, Pedraza, E.1, Rosales, C.1, Rosales, M.1,
Esguerra, H.1, Figueroa, J.1, Rubio, A.2 1Clınica de Marly, Bogota, Co-
lombia; 2Universidad Nacional de Colombia, Bogota, Colombia
Objectives: The aim of this study is to report outcomes of patients
with Hodgkin Disease (HD) after high dose therapy and autologous
Hematopoietic Stem Cell Transplantation (auto-HSCT) in a single
center in Colombia.
Methods: One hundred four patients with relapsed or refractory
HDwere treated with auto-HSCT between 1994 and 2008. Clinical
status previous to transplantation, and events as relapse or deathwere
analyzed to establish 5 year Overall Survival (OS) and Event Free
Survival (EFS).
Results: One hundred four patients have had 105 procedures (one
patient with 2 auto-SCT). Thirty-five female and 69 male, 79 adults
and 25 less than 16 years, with average age of 27.4 years (range 5 to 66
yrs). Forty-one patients (39,4%) with refractory disease, 21 with
early relapse (20%) and 42 with late relapse (40,4%).
Clinical stage at diagnosis: I and IIA 24 patients (23%), IIB 28 pa-
tients (26.9%), IIIA 7 patients (6.7%), III B 21 patients (20%), stage
IV 21 patients (20%) and (3 patients unknown). The source of cells
was peripheral blood in 95 transplants (91.4%), bone marrow in 6
(5.7%) and combined in 2 procedures (1.9%) combined, (2 patients
unknown).
The conditioning chemotherapy was BEAM in 56 transplants
(53.3%), cyclophosphamyde-etoposide-melphalan in 26 (24.7%)
and other protocols in 23 (21.9%) transplants. At the time of trans-
plantation, 61 patients (58%) were in complete remission, 36 (34%)
in partial remission and 5 (4.7%) with active disease.
Twenty nine patients had relapse, of them 11 are dead. Seven
patients had non relapse mortality: 5 with infectious complications,
1 with colecistitis and 1 with graft failure. Two patients died for
complications of a second neoplasm. The mortality in the first
100-days was 3% (3 patients with infectious complications).
With a median of 971 days of follow-up (range 12 to 5587
days), 59 (56.7%) patients are in complete remission, 17 (16.3%)
are alive after relapse, 21 (20.1%) have died and 7 (6.7%) were
lost for follow-up.
